Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 12-Week therapy aims to tackle trauma and addiction together

NCT ID NCT07193914

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a 12-week group therapy program called ECCCLORE for people who have both post-traumatic stress disorder (PTSD) and addiction. The program combines skills for managing emotions, distress, and relationships. Researchers want to see if it is feasible and acceptable for patients. 30 adults will participate, attending weekly group sessions plus short individual check-ins.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ECCCLORE program (cognitive behavioral therapy group sessions)
What this could lead to
If successful, this could provide a shorter, group-based therapy option that helps people manage both trauma and addiction together.
What could go wrong
This is a very small, early feasibility study with only 30 participants, so results may not apply widely. The program may not be acceptable or practical for many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with one or more addictions * ASSIST questionnaire score greater than or equal to 11 for alcohol consumption and greater than or equal to 4 for other substances. * Diagnosis of PTSD and/or CPTSD assessed using the ITQ scale. * Ability to understand, write, and read French * The patient must have given their free and informed consent * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * The subject is participating in an interventional study involving a drug or medical device or a Category 1 study within 3 months prior to inclusion * The patient is under safeguard of justice or state guardianship * Patients with a psychotic disorder * Patients with severe cognitive impairment (MoCA \< 10) * Patients experiencing a manic or hypomanic episode * Patients experiencing a major depressive episode * Patients participating in an interventional study involving a drug or medical device or a Category 1 RIPH within 3 months prior to inclusion * Pregnant, parturient, or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Addiction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior, Addictive post-traumatic stress disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Addiction CBT PTSD Substance use disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nîmes

    RECRUITING

    Nîmes, Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.